Professor Xiaokong Liu's team at Jilin University proposed an "activation-quenching" strategy for dynamic covalent chemistry, achieving precise and controllable "on-off" switching of dynamic bond ...
BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...
Allyl isothiocyanate, the pungent principle of wasabi and other mustard oils, produces pain by activating TRPA1, an excitatory ion channel on sensory nerve endings. Isothiocyanates are ...
Jaypirca is the first BTK inhibitor of any kind specifically approved for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor In the BRUIN Phase 1/2 trial, covalent BTK ...
This study is led by Prof. Xian-Xiang Zeng (School of Chemistry and Materials Science, Hunan Agricultural University) and Prof. Xiong-Wei Wu (School of Chemistry and Materials Science, Hunan ...